Adverum Biotechnologies | LinkedIn (original) (raw)

Biotechnology Research

Redwood City, California 11,852 followers

We are on a global mission to establish gene therapy as a new standard of care for the leading causes of vision loss.

Discover all 174 employees

About us

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.

Industry

Biotechnology Research

Company size

51-200 employees

Headquarters

Redwood City, California

Type

Public Company

Founded

2012

Specialties

Gene Therapy, Biotechnology, Rare Diseases, Ophthalmology, and Retina

Locations

Employees at Adverum Biotechnologies

Updates

Adverum is heading to Hawaiian Eye & Retina 2025 and we’d love to see you there! We’ll be sharing an update on Ixo-vec, our single-injection #genetherapy candidate for treatment of patients with #wetAMD. Catch our presentations: ● Dr. Lejla Vajzovic, MD, FASRS will share insights during the Disruptive Innovation Symposium on January 20, from 1:55 – 2:00 PM in the Grand Ballroom 3, 4, 5 (Ground Level). ● Dr. Glenn Yiu will present "Ixo-vec IVT Gene Therapy for nAMD: P2 LUNA Study Update" on January 21, from 10:01 – 10:07 AM, in the Grand Ballroom 3, 4, 5 (Ground Level). If you’re attending, stop by booth 121 on Retina Row—let’s connect!
Later this week our team is headed to the #FLORetina in Florence, Italy, where we’ll present 52-week data from our LUNA Phase 2 trial of Ixo-vec. Ixo-vec is our single-injection #genetherapy candidate for treatment of patients with #wetAMD. Learn more: https://bit.ly/3UTE24c
We are thrilled to announce positive 52-week LUNA Phase 2 data and 4-year OPTIC clinical data that continue to establish Ixo-vec as a transformative and potential best-in-class therapy, potentially providing patients who have wet AMD with life-long benefit and a predictable safety profile. Additionally, we are excited to share details for our pivotal program and look forward to initiating Phase 3 in 1H 2025. Learn more and find the link to the webcast here: https://bit.ly/3UTE24c #genetherapy #Biotech #wAMD
Yesterday, we announced that on Monday, November 18th we’ll be sharing 52-week data from our Phase 2 LUNA trial, 4-year data from our OPTIC trial and key design elements from our upcoming Phase 3 pivotal trial. Join our webcast Monday morning to learn more. Learn more here: https://bit.ly/4fuzCsK #genetherapy #Biotech #wAMD
Today, Team Adverum had the opportunity to volunteer with Samaritan House, helping prepare and distribute food for community members in need. As Adverians, we aim to make this world a better place, whether it’s helping to address food insecurity in our community or working to change the treatment paradigm for millions of patients living with wet AMD. #AdverumGivesBack
Today, Adverum Biotechnologies reported our third quarter financial results and updated anticipated milestones. Read here for more details: https://bit.ly/4fxolaq
Last week, we had the opportunity to present at AAO’s Eyecelerator, where we shared exciting data on Ixo-vec, our gene therapy product candidate for the treatment of wet AMD. A big thank you to the American Academy of Ophthalmology, Eyecelerator, and the retinal community for their continued support and collaboration. We’re honored to contribute to groundbreaking efforts in ophthalmology and strive to set a new standard of care. Stay tuned for 52-week LUNA data and updates on our Phase 3 program later this year!
We're excited to welcome Jason Mitchell to our leadership team as Chief Commercial Officer! With 20+ years of commercial experience, including recently building and leading the team for one of the most successful launches in advanced #retinaldisease, Jason’s experience will be invaluable as we prepare to initiate our pivotal program in #wetAMD. Learn more here: https://bit.ly/3YmUonT
We are beyond thrilled to share that we've been recognized as one of the Bay Area's Top Workplaces for the fourth year in a row! This achievement is a testament to our incredible team and the vibrant, inclusive culture we've built together. Thank you to every member of #TeamAdverum for making this possible. Here's to continuing our journey of pioneering, collaboration, and excellence!
Join Adverum’s President and CEO Laurent Fischer, M.D., for a fireside chat at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, where he’ll share our latest company highlights. Learn more here: https://bit.ly/3SyyaMA #genetherapy #wetAMD

Join now to see what you are missing

Join now

Adverum Biotechnologies | LinkedIn (original) (raw)

Biotechnology Research

Redwood City, California 11,852 followers

We are on a global mission to establish gene therapy as a new standard of care for the leading causes of vision loss.

About us

Locations

Employees at Adverum Biotechnologies

Updates

Join now to see what you are missing

Similar pages

Browse jobs

Funding